A report in Bloomberg cites a registration in the Chinese Clinical Trial Registry confirming that the nasal spray vaccine candidate developed by Xiamen University, Hong Kong University and Beijing Wantai Biological Pharmacy Enterprise is undergoing Phase I human testing.
IN CASE YOU MISSED IT
- Insulet expands Omnipod 5 to more countries, prices $450M offering
- Sequel Med Tech makes first CGM integration with Abbott for automated insulin pump
- Vivani reports first human GLP-1 implant for weight loss in adults
- Trinity Biotech to undergo strategic realignment, focus on CGM development
- Vivani to spin out neurostim business, focus on GLP-1 implant
About Sean Whooley
Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.